T

he number of so-called pay-to-delay deals declined in fiscal year 2015, the second consecutive year that a drop occurred since the U.S. Supreme Court ruled these controversial agreements can be subject to antitrust scrutiny, according to the latest tally by the Federal Trade Commission.

The FTC has kept a watchful eye on these deals, which involve settlements of patent litigation between brand-name and generic drug makers, over concerns that some violate antitrust laws. The agency, which has gone to court several times to argue this point, has in the past claimed these deals cost U.S. consumers an estimated $3.5 billion annually.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.